Claims for Patent: 4,405,598
✉ Email this page to a colleague
Summary for Patent: 4,405,598
| Title: | Composition for treating asthma |
| Abstract: | There is described a method of treatment of asthma which comprises administration to an asthmatic patient of an effective amount of an inhalation composition consisting essentially of a dispersion or suspension of from 0.2 to 2.0% disodium cromoglycate of mass median diameter 0.01 to 10 microns, from 0.15 to 2.0% by weight of a sorbitan or sorbitol ester surfactant and a propellant mixture comprising dichlorodifluoromethane and 1,2-dichloro-1,1,2,2-tetrafluoroethane, the ratio of dichlorodifluoromethane to 1,2-dichloro-1,1,2,2-tetrafluoroethane, in said mixture being in the range from 2:1 to 1:1 by weight, the disodium cromoglycate used in the formulation containing from 0.05 to 1% w/w of water and the total formulation containing less than 0.1% w/w of water and having a vapor pressure in the range 35 to 70 pounds per square inch gauge. There is also described disodium cromoglycate having a mass median diameter of less than 20 microns, more preferably in the range 0.01 to 10 microns, and most preferably at least 50% by weight of the particles having a diameter of 2 to 5 microns and containing less than 1% by weight of water. |
| Inventor(s): | Kenneth Brown |
| Assignee: | Fisons Ltd |
| Application Number: | US06/224,747 |
| Patent Claims: |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch